Pro-Dex, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013, compared with fiscal 2012. The request metadata says “2012 Q4,” but the supplied filing is an annual report for fiscal 2013, not a quarterly filing.
Business context
Pro-Dex designs and manufactures powered surgical and dental instruments and motion-control products. Continuing operations are principally in medical, industrial, dental, and government/other markets. The Astromec fractional-horsepower motor business was sold in February 2012 and is reported as a discontinued operation.
Financial performance and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Net sales | $12.249 million | $17.257 million |
| Gross profit / margin | $3.716 million / 30% | $5.416 million / 31% |
| Operating expenses | $5.611 million | $6.781 million |
| Loss from continuing operations | $1.864 million | $960,000 |
| Net loss | $1.784 million | $876,000 |
| Operating cash flow | $(1.271) million | $45,000 |
| Cash at year-end | $1.680 million | $4.112 million |
| Working capital | $5.033 million | $6.618 million |
| Total debt | No bank term loan; $20,000 capital-lease obligations | $774,000 bank term loan |
- Sales fell 29% year over year. The reduction in sales to the former largest customer was the main factor; gross profit also declined, while gross margin decreased by about one percentage point.
- Operating cash use reflected, in particular, a $1.043 million inventory increase and $244,000 of unbilled receivables. Cash declined by $2.432 million during the year.
- The company repaid its remaining $685,000 bank term loan in September 2012 and terminated its credit facilities. It had no bank credit facility at fiscal year-end.
- Fiscal 2013 included a $176,000 accrual for anticipated development-contract losses. A $39,000 income-tax benefit was recognized, versus $441,000 in fiscal 2012; deferred tax assets were fully valuation-allowed.
Changes, outlook, and risks
- The former largest customer’s product sales ended by May 2012 as it developed its own devices. Pro-Dex reported $722,000 of repair revenue from that customer in FY 2013, versus $6.710 million in FY 2012; the customer could stop ordering repairs.
- Customer concentration remains significant: the filing reports the largest customer at 47% of FY 2013 sales in its customer table, while a business-section passage says 46%. The top 20 customers represented 81% of sales.
- Management believed existing cash and operating cash flows would fund operations for the next 12 months, while warning that lower-than-anticipated cash flows could impair liquidity and necessitate financing that might not be available on acceptable terms.
- Backlog was $6.7 million at June 30, 2013, versus $5.3 million a year earlier. Management cautioned that order bookings vary and gave no specific revenue or earnings guidance.
- Management said the largest customer had deferred product orders, prolonging a build-up of customer-specific inventory; partial relief was expected mainly in the latter half of FY 2014 and possibly the first half of FY 2015, subject to customer demand.
- After year-end, the company sold the former Astromec facility for $980,000, receiving approximately $915,000 net proceeds in July 2013. In September 2013, the board authorized repurchases of up to 750,000 shares, with no stated expiration date.
- The company invested in publicly traded equities under a new surplus-capital policy. The filing identifies potential conflicts because investment committee members had interests in some of the same companies; it also warns of volatility and limited liquidity in these securities.
- Other disclosed risks include medical-device regulation and healthcare reform, competition and technological change, supplier dependence, key-personnel retention, possible environmental exposure at a former site, and Nasdaq listing-price risk. DTSC reported no further evaluation of the former Santa Ana site during FY 2011–2013; potential future exposure is unclear.
- Management reported effective disclosure controls and internal control over financial reporting as of June 30, 2013. The independent auditor issued an unqualified opinion on the financial statements.
Investor verification priorities
- Confirm the true period being analyzed: this filing covers the year ended June 30, 2013, not 2012 Q4.
- Reconcile the 46% versus 47% disclosure for the largest customer and assess ongoing orders, repair revenue, and customer-specific inventory exposure.
- Review cash burn, inventory conversion, backlog quality, and the assumptions supporting management’s 12-month liquidity assessment, including the subsequent real-estate proceeds.
- Examine the development-contract loss accrual, revenue-recognition timing for engineering services, and the full valuation allowance on deferred tax assets.
- Assess the investment policy’s concentration, liquidity, valuation, and related-party conflict risks, as well as the terms and actual use of the share-repurchase authorization.